Your browser is no longer supported. Please, upgrade your browser.
Settings
ASRT Assertio Therapeutics, Inc. daily Stock Chart
ASRT [NASD]
Assertio Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.77 Insider Own0.70% Shs Outstand80.73M Perf Week-5.52%
Market Cap61.71M Forward P/E0.92 EPS next Y0.83 Insider Trans9.47% Shs Float79.60M Perf Month-12.15%
Income-48.70M PEG- EPS next Q0.17 Inst Own85.80% Short Float12.61% Perf Quarter-49.71%
Sales212.90M P/S0.29 EPS this Y146.80% Inst Trans13.59% Short Ratio6.14 Perf Half Y-77.52%
Book/sh3.42 P/B0.22 EPS next Y-6.74% ROA-5.80% Target Price5.50 Perf Year-85.82%
Cash/sh- P/C- EPS next 5Y25.00% ROE-22.30% 52W Range0.70 - 5.76 Perf YTD-78.83%
Dividend- P/FCF0.65 EPS past 5Y-5.20% ROI13.30% 52W High-86.73% Beta1.82
Dividend %- Quick Ratio0.60 Sales past 5Y18.40% Gross Margin96.40% 52W Low9.04% ATR0.11
Employees116 Current Ratio0.60 Sales Q/Q-28.90% Oper. Margin4.60% RSI (14)39.33 Volatility12.69% 11.72%
OptionableYes Debt/Eq1.47 EPS Q/Q-92.20% Profit Margin-22.90% Rel Volume0.64 Prev Close0.80
ShortableYes LT Debt/Eq1.15 EarningsNov 06 AMC Payout- Avg Volume1.63M Price0.76
Recom2.70 SMA20-7.85% SMA50-29.58% SMA200-73.87% Volume1,041,334 Change-4.33%
Nov-30-18Downgrade Mizuho Buy → Neutral
Nov-13-19 12:58PM  Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference GlobeNewswire +11.25%
Nov-07-19 11:26AM  PDL BioPharma (PDLI) Q3 Earnings Beat, LENSAR Drives Sales Zacks
Nov-06-19 07:45PM  Assertio (ASRT) Surpasses Q3 Earnings Estimates Zacks -12.08%
04:05PM  Assertio Therapeutics Announces Third-Quarter 2019 Results GlobeNewswire
Nov-04-19 06:05AM  How Much Did Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) CEO Pocket Last Year? Simply Wall St.
Oct-30-19 06:35PM  Ceridian HCM Holding, BJ's Wholesale Club Holdings Set to Join S&P MidCap 400; Oceaneering International, Covetrus to Join S&P SmallCap 600 PR Newswire
10:34AM  Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-23-19 09:05AM  Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019 GlobeNewswire
Oct-22-19 07:51AM  The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug Benzinga
Oct-21-19 09:05AM  Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin GlobeNewswire -28.13%
Oct-13-19 04:33PM  The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings Benzinga
Oct-05-19 09:54AM  How Does Assertio Therapeutics, Inc. (NASDAQ:ASRT) Affect Your Portfolio Volatility? Simply Wall St.
Sep-30-19 12:35PM  Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors GlobeNewswire
Sep-26-19 08:00AM  Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-24-19 05:38PM  Medicenna Strengthens Board of Directors by Appointment of Seasoned Biopharma Executive Ms. Karen Dawes CNW Group
Sep-20-19 09:40AM  ASRT vs. ZTS: Which Stock Is the Better Value Option? Zacks
Sep-09-19 09:50AM  Top Ranked Value Stocks to Buy for September 9th Zacks
Sep-05-19 11:05AM  If You Had Bought Assertio Therapeutics (NASDAQ:ASRT) Stock Three Years Ago, You'd Be Sitting On A 94% Loss, Today Simply Wall St.
Sep-04-19 09:30AM  ASRT vs. ZTS: Which Stock Should Value Investors Buy Now? Zacks
Aug-20-19 08:00AM  Assertio Therapeutics to Present at the 17th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire -16.87%
07:59AM  Assertio Therapeutics Enters Oversold Territory Zacks
Aug-19-19 09:30AM  ASRT vs. PCRX: Which Stock Is the Better Value Option? Zacks
Aug-12-19 09:15PM  Assertio Therapeutics Inc (ASRT) Director, President and CEO Arthur J Higgins Bought $77,000 of ... GuruFocus.com
Aug-09-19 09:28AM  Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021 GlobeNewswire -45.91%
Aug-08-19 11:24PM  Assertio Therapeutics, Inc (ASRT) Q2 2019 Earnings Call Transcript Motley Fool +5.64%
Aug-07-19 07:35PM  Assertio (ASRT) Q2 Earnings Beat Estimates Zacks
04:02PM  Assertio Therapeutics Announces Strong Second-Quarter 2019 Results GlobeNewswire
Aug-06-19 03:22PM  Is Assertio Therapeutics (NASDAQ:ASRT) A Risky Investment? Simply Wall St.
Jul-31-19 10:36AM  Assertio (ASRT) Earnings Expected to Grow: Should You Buy? Zacks
Jul-26-19 09:30AM  ASRT or AMRX: Which Is the Better Value Stock Right Now? Zacks
Jul-17-19 04:05PM  Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019 GlobeNewswire -8.38%
Jul-01-19 08:39AM  La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza Zacks
Jun-23-19 08:53PM  Heres What Hedge Funds Think About Assertio Therapeutics, Inc. (ASRT) Insider Monkey
Jun-22-19 10:37AM  Have Insiders Been Buying Assertio Therapeutics, Inc. (NASDAQ:ASRT) Shares? Simply Wall St.
Jun-13-19 09:50AM  Savara Plunges on Failure of Late-Stage Study on Molgradex Zacks
May-20-19 10:28AM  ASSERTIO THERAPEUTICS Enters Oversold Territory Zacks
May-14-19 09:30AM  Is ASSERTIO THERAPEUTICS, INC (ASRT) Stock Outpacing Its Medical Peers This Year? Zacks
May-09-19 11:24AM  Assertio Therapeutics, Inc (ASRT) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 05:25PM  Assertio (ASRT) Tops Q1 Earnings and Revenue Estimates Zacks
04:17PM  Assertio: 1Q Earnings Snapshot Associated Press
04:02PM  Assertio Therapeutics Announces First-Quarter 2019 Financial Results GlobeNewswire
May-06-19 11:54AM  Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up? Zacks
May-01-19 10:33AM  Analysts Estimate Assertio (ASRT) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-24-19 04:46PM  Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019 GlobeNewswire
Apr-23-19 08:22AM  What Assertio Therapeutics, Inc.'s (NASDAQ:ASRT) ROE Can Tell Us Simply Wall St.
Apr-16-19 07:17PM  Achaogen (AKAO) Files for Bankruptcy, Shares Plunge 65% Zacks
Apr-01-19 09:00AM  Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors GlobeNewswire
Mar-28-19 06:12PM  Magellan Health nears board deal with hedge fund Starboard Value - sources Reuters +6.62%
01:51PM  Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling GlobeNewswire
Mar-26-19 07:37AM  Will Assertio Therapeutics Continue to Surge Higher? Zacks -6.16%
Mar-25-19 06:30PM  Weekly CFO Buys Highlight GuruFocus.com
Mar-22-19 11:23AM  Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan Zacks
Mar-14-19 09:10AM  New Strong Buy Stocks for March 13th Zacks
Mar-11-19 09:48AM  Assertio Therapeutics Inc (ASRT) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -5.74%
Mar-06-19 11:49PM  Assertio Therapeutics, Inc (ASRT) Q4 2018 Earnings Conference Call Transcript Motley Fool
04:02PM  Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2018 Financial Results GlobeNewswire
02:30PM  Depomed, Inc. to Host Earnings Call ACCESSWIRE
Mar-01-19 04:52PM  Intellia CEO not involved in Starboard's Bristol-Myers board challenge Reuters
Feb-21-19 04:05PM  Assertio Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results After The Close of Markets on Wednesday, March 6, 2019 GlobeNewswire -6.86%
Feb-19-19 08:30AM  Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin GlobeNewswire
08:00AM  Assertio Therapeutics Announces Appointment of Heather L. Mason to Board of Directors GlobeNewswire
Feb-15-19 09:30AM  ASRT or COLL: Which Is the Better Value Stock Right Now? Zacks
Jan-30-19 09:30AM  ASRT vs. COLL: Which Stock Should Value Investors Buy Now? Zacks
Jan-22-19 07:32AM  Top Ranked Growth Stocks to Buy for January 22nd Zacks
Jan-18-19 09:36AM  Top Ranked Growth Stocks to Buy for January 18th Zacks
Jan-14-19 09:30AM  ASRT vs. COLL: Which Stock Should Value Investors Buy Now? Zacks
Jan-09-19 07:00AM  Assertio Therapeutics Announces Amendment of its Senior Secured Credit Facility GlobeNewswire -6.82%
Dec-20-18 09:00AM  Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot GlobeNewswire
Nov-13-18 02:57PM  Should You Be Concerned About Assertio Therapeutics Incs (NASDAQ:ASRT) Historical Volatility? Simply Wall St.
Nov-08-18 07:28PM  Assertio: 3Q Earnings Snapshot Associated Press
04:06PM  Assertio Therapeutics Announces Third-Quarter 2018 Financial Results GlobeNewswire
Oct-29-18 04:05PM  Assertio Therapeutics Announces the Appointment of Daniel A. Peisert as Senior Vice President and Chief Financial Officer; Current CFO Phil B. Donenberg to Retire November 30, 2018 GlobeNewswire
Oct-23-18 09:30AM  ASRT vs. IPSEY: Which Stock Is the Better Value Option? Zacks
Oct-17-18 08:00AM  Assertio Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Oct-09-18 01:04PM  Opioid antidote inventor: We're in the 'next phase of this opioid crisis' Yahoo Finance
Oct-08-18 07:00AM  Assertio Therapeutics to Report Third-Quarter 2018 Financial Results After The Close of Markets on Thursday, November 8, 2018 GlobeNewswire
Sep-13-18 01:09PM  Healthcare Industry Trends And Its Impact On Assertio Therapeutics Inc (NASDAQ:ASRT) Simply Wall St.
Sep-05-18 08:00AM  Assertio Therapeutics to Present at the 16th Annual Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-28-18 04:36PM  Assertio Therapeutics and Purdue Pharma Settle Patent Infringement Lawsuit GlobeNewswire
Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018. Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HIGGINS ARTHUR JDirector, President and CEONov 12Buy0.7325,00018,250112,879Nov 12 04:36 PM
STAPLE PETER DDirectorNov 11Buy0.7113,9009,91113,900Nov 12 04:36 PM
Peisert Daniel A.SVP and CFONov 11Buy0.7310,0007,25974,873Nov 12 04:36 PM